In today’s session Mylan NV (MYL) registered an unusually high (1,025) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious MYL increase. With 1,025 contracts traded and 52314 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: MYL161118C00042500 closed last at: $0.3 or 16.7% down. About 1.53M shares traded hands. Mylan NV (NASDAQ:MYL) has declined 20.89% since March 29, 2016 and is downtrending. It has underperformed by 24.36% the S&P500.
Analysts await Mylan NV (NASDAQ:MYL) to report earnings on November, 4. They expect $1.60 EPS, up 11.89% or $0.17 from last year’s $1.43 per share. MYL’s profit will be $856.05M for 5.78 P/E if the $1.60 EPS becomes a reality. After $1.16 actual EPS reported by Mylan NV for the previous quarter, Wall Street now forecasts 37.93% EPS growth.
Mylan NV (NASDAQ:MYL) Ratings Coverage
Out of 16 analysts covering Mylan Inc. (NASDAQ:MYL), 10 rate it a “Buy”, 0 “Sell”, while 6 “Hold”. This means 63% are positive. $85 is the highest target while $46 is the lowest. The $59.80 average target is 61.75% above today’s ($36.97) stock price. Mylan Inc. has been the topic of 27 analyst reports since July 27, 2015 according to StockzIntelligence Inc. The rating was initiated by Standpoint Research with “Buy” on Wednesday, August 26. On Friday, February 19 the stock rating was initiated by Wells Fargo with “Market Perform”. The stock has “Equal Weight” rating given by Barclays Capital on Monday, September 21. The company was maintained on Wednesday, May 4 by Leerink Swann. Morgan Stanley reinitiated Mylan NV (NASDAQ:MYL) on Thursday, December 3 with “Equal-Weight” rating. The company was maintained on Tuesday, September 6 by RBC Capital Markets. The stock of Mylan NV (NASDAQ:MYL) earned “Strong Buy” rating by Raymond James on Monday, October 10. Leerink Swann maintained the shares of MYL in a report on Saturday, August 29 with “Outperform” rating. The stock of Mylan NV (NASDAQ:MYL) has “Buy” rating given on Friday, August 7 by Argus Research. The rating was maintained by UBS with “Buy” on Monday, October 10.
According to Zacks Investment Research, “Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.”
Insitutional Activity: The institutional sentiment decreased to 0.45 in 2016 Q2. Its down 0.05, from 0.5 in 2016Q1. The ratio turned negative, as 6 funds sold all Mylan NV shares owned while 5 reduced positions. 1 funds bought stakes while 4 increased positions. They now own 533,685 shares or 37.96% less from 860,251 shares in 2016Q1.
Eagle Asset Mngmt owns 56,209 shares or 0.02% of their US portfolio. Moreover, Gulf Financial Bank (Uk) Ltd has 0.09% invested in Mylan NV (NASDAQ:MYL) for 123,183 shares. Westport Resource owns 26,765 shares or 0.37% of their US portfolio. Jacobs Ca has 7,305 shares for 0.07% of their US portfolio. Covington Capital Mgmt has invested 0.16% of its portfolio in Mylan NV (NASDAQ:MYL). Princeton Strategies Group Incorporated Ltd Liability Corporation holds 1.89% of its portfolio in Mylan NV (NASDAQ:MYL) for 135,477 shares. Ntv Asset Llc reported 15,990 shares or 0.26% of all its holdings. Vantage Inv Advsrs Limited Liability Corp, a Pennsylvania-based fund reported 712 shares. Gemmer Asset Ltd holds 0% of its portfolio in Mylan NV (NASDAQ:MYL) for 21 shares. American Mgmt Co accumulated 0.03% or 1,600 shares. Icon Advisers last reported 35,000 shares in the company. Novare Capital Limited Liability Co has 79,851 shares for 0.93% of their US portfolio.
Mylan N.V. is a global pharmaceutical company. The company has a market cap of $19.78 billion. The Firm develops, licenses, makes, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients . It has a 23.5 P/E ratio. It operates through two divisions: Generics and Specialty.
MYL Company Profile
Mylan N.V., incorporated on July 7, 2014, is a global pharmaceutical company. The Firm develops, licenses, makes, markets and distributes generic, branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). The Firm operates through two divisions: Generics and Specialty. The principal markets for Generics are pharmaceutical wholesalers and distributors; group purchasing organizations; drug store chains; independent pharmacies; drug manufacturers; institutions, and public and governmental agencies primarily within the United States and Canada (collectively, North America); Europe, and India, Australia, Japan, New Zealand and Brazil (collectively, Rest of World). The Generics segment also focuses on developing API with non-infringing processes for both internal use and to partner with manufacturers in regulated markets, such as the United States and the European Union at market formation. The principal market for Specialty is pharmaceutical wholesalers and distributors, pharmacies and healthcare institutions primarily in the United States.
More notable recent Mylan NV (NASDAQ:MYL) news were published by: Investorplace.com which released: “Mylan NV (MYL) Stock Holders Can Shrug Off Kaleo’s EpiPen Threat” on October 27, 2016, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” published on October 06, 2016, Investorplace.com published: “Why Alphabet Inc (GOOG), Mylan NV (MYL) And Tesaro Inc (TSRO) Are 3 of Today’s …” on October 10, 2016. More interesting news about Mylan NV (NASDAQ:MYL) were released by: Profitconfidential.com and their article: “Mylan NV: MYL Stock Chart Has Ominous Implications” published on October 04, 2016 as well as Investorplace.com‘s news article titled: “3 Stocks to Watch Monday: Mylan NV (MYL), Bristol-Myers Squibb Co (BMY) and …” with publication date: October 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.